Amid the IPO market’s annual August break, five very small issuers raised a combined $42 million, well below the typically-slow month’s 10-year average (10 IPOs, $1.9B). The lineup included four traditional IPOs, all of which finished below issue,...read more
MIRA Pharmaceuticals, a preclinical developer of molecular synthetic THC analogs for anxiety and neurologic indications, raised $9 million by offering 1.3 million shares at $7.00, as expected. The company originally filed to offer 1.0 million shares at a range...read more
MIRA Pharmaceuticals, a preclinical biotech developing a molecular synthetic THC analog for anxiety and neuro indications, raised the proposed deal size for its upcoming IPO on Friday. The Baltimore, MD-based company now plans to raise $8 million by offering...read more
Renaissance Capital's August IPO Market Update
Amid the IPO market’s annual August break, five very small issuers raised a combined $42 million, well below the typically-slow month’s 10-year average (10 IPOs, $1.9B). The lineup included four traditional IPOs, all of which finished below issue,...read more
US IPO Weekly Recap: SharkNinja completes listing as wave of small IPOs continues
There were five pricings this past week, four of which are included in our IPO stats. Three issuers submitted initial filings. With ...read more
Budding THC drug developer MIRA Pharmaceuticals prices IPO at $7
MIRA Pharmaceuticals, a preclinical developer of molecular synthetic THC analogs for anxiety and neurologic indications, raised $9 million by offering 1.3 million shares at $7.00, as expected. The company originally filed to offer 1.0 million shares at a range...read more
Cannabis-focused MIRA Pharmaceuticals ups share offering by 20% ahead of $8 million IPO
MIRA Pharmaceuticals, a preclinical biotech developing a molecular synthetic THC analog for anxiety and neuro indications, raised the proposed deal size for its upcoming IPO on Friday. The Baltimore, MD-based company now plans to raise $8 million by offering...read more